Nemluvio Shortage Update: What Patients Need to Know in 2026

Patients prescribed Nemluvio (nemolizumab-ilto) often hear that the drug is "not available" at their local pharmacy, and many assume a shortage is to blame. The reality is more nuanced — and knowing the difference can help you take the right steps to get your medication.

Is Nemluvio Currently in Shortage? (2026 Update)

As of 2026, Nemluvio is not listed on the FDA's official drug shortage database. Galderma, the manufacturer, reports that supply through its specialty pharmacy network remains stable. There are no known manufacturing disruptions, raw material shortages, or distribution breakdowns affecting Nemluvio supply as of this writing.

However, the drug is still relatively new (FDA approved in August 2024 for prurigo nodularis and expanded to atopic dermatitis in December 2024), and its specialty-only distribution model means it simply isn't accessible at the vast majority of pharmacies. This is not a shortage — it's a distribution design.

Why Does It Feel Like Nemluvio Is in Shortage?

Several factors create the impression of a shortage even when one doesn't technically exist:

Retail pharmacy gaps: Nemluvio is not sold at standard retail pharmacies. If you call a CVS or Walgreens, they simply don't carry it — and may say it's unavailable, which patients understandably interpret as a shortage.

Prior authorization delays: Insurance companies can take days or weeks to approve a PA for a new, expensive biologic. During this wait, patients feel "stuck" — not because of a shortage but because of administrative hurdles.

Enrollment not yet completed: Nemluvio requires enrollment in the GPS (Galderma Patient Services) program before a specialty pharmacy can dispense it. If this form hasn't been submitted by your doctor's office, you will not receive the drug regardless of supply.

New drug learning curve: Nemluvio was only approved in late 2024. Some prescribers and pharmacies are still becoming familiar with the enrollment and dispensing process, leading to extra delays.

Nemluvio's Approval History and Why Timing Matters

Nemluvio received FDA Breakthrough Therapy Designation in 2019 for prurigo nodularis and Priority Review in February 2024, reflecting the FDA's view that it addressed a serious unmet medical need. The August 12, 2024 approval for PN was followed in December 2024 by expanded approval for atopic dermatitis.

Because Nemluvio is so new, insurance formularies are still catching up. Some insurance plans — particularly older formulary designs — may not yet have a clear pathway for Nemluvio coverage, leading to PA denials or step therapy requirements that must be overcome before the drug is accessible.

What to Do If You Can't Get Nemluvio Right Now

Confirm GPS enrollment: Call your dermatologist's office and confirm the GPS for Nemluvio enrollment form has been submitted to Galderma.

Request Quick Start: Ask if you qualify for the Quick Start program to receive initial doses while PA is pending.

Appeal a PA denial: If your insurance denied coverage, your dermatologist can submit a letter of medical necessity and request a peer-to-peer review.

Consider the Bridge Program: GPS for Nemluvio offers bridge supplies if you experience a gap in treatment due to insurance changes or delays.

Ask about alternatives: If you need immediate treatment while sorting out Nemluvio access, ask your dermatologist about Dupixent or other approved options in the meantime.

Could Nemluvio Face a Future Shortage?

All biologic medications carry some supply risk. Nemluvio is produced in Chinese Hamster Ovary (CHO) cells using recombinant DNA technology, which is a complex manufacturing process. Any disruption at the production facility or supply chain could theoretically create a shortage. However, Galderma has invested significantly in Nemluvio as a flagship product, and no warnings or supply concerns have been issued.

How medfinder Helps When Access Is Uncertain

Whether you're facing a specialty pharmacy navigation challenge or trying to find a backup option, medfinder can help by contacting pharmacies on your behalf to determine availability. If Nemluvio access remains blocked, see our guide on alternatives to Nemluvio for FDA-approved treatment options to discuss with your doctor.